Navigation Links
ARCADIS' Jane Staveley to Moderate Congressional Briefing on Pharmaceuticals in Drinking Water

DENVER, Sept. 14 /PRNewswire/ -- Jane Staveley, a Principal Environmental Scientist for ARCADIS (EURONEXT: ARCAD), the international consultancy, design, engineering and management services company, will moderate a distinguished panel of experts on the topic of "Pharmaceuticals in Our Water: Concerns and Responses" during a briefing in the Rayburn House Office Building today, September 14. The briefing will be held from noon to 1:30 p.m. and is presented by the American Chemical Society's Science & the Congress Project, the Society for Risk Analysis and the Society of Toxicology, with honorary co-host, the House Science and Technology Committee.



With a focus on the presence of pharmaceuticals in waterways and drinking water throughout the United States, the briefing is designed to explore what is known about the relative contributions from different types of drugs, their persistence in the environment, and the best methods of drug disposal to reduce the amount getting into the environment.  

"I look forward to guiding the panelists in this important discussion as we explore what is known and still unknown about the potential impacts of water-borne pharmaceuticals on human health and ecological receptors," said Staveley. "We also will discuss what steps can be taken to maintain the health benefits of drugs, while at the same time mitigating any unintended consequences from their presence in our water."

Renowned scientists comprising the panel include Mae Wu from the Natural Resources Defense Council; Shane Snyder from the University of Arizona; Sierra Fletcher from the Product Stewardship Institute; and Richard Williams, formerly of Pfizer, Inc.

Staveley brings a wealth of knowledge to her role as moderator, given her more than 30 years of experience in both the public and private sectors working on myriad environmental issues. In addition to her role with ARCADIS, she is currently the President of the Society of Environmental Toxicology and Chemistry (SETAC) and is active in SETAC's advisory group on Pharmaceuticals in the Environment.

For more information, please contact Jeanna Blatt of ARCADIS at 303.471.3485 or


ARCADIS is an international company providing consultancy, design, engineering and management services in infrastructure, water, environment and buildings. We enhance mobility, sustainability and quality of life by creating balance in the built and natural environment. ARCADIS develops, designs, implements, maintains and operates projects for companies and governments. With 15,000 employees and over $2.4 billion in revenues, the company has an extensive international network supported by strong local market positions. ARCADIS supports UN-HABITAT with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. Visit us at:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
2. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
3. PTSD Associated With Higher Alzheimers/Dementia Risk; Moderate Alcohol Consumption May Lower it
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
6. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
7. Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
8. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
9. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
10. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
11. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
Breaking Medicine News(10 mins):